Logo image
DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC - US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM
Abstract   Peer reviewed

DAROLUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): ARASEC - US PROSPECTIVE, OPEN-LABEL PHASE 2 STUDY WITH AN EXTERNAL CONTROL ARM

Rana R. McKay, Ashley E. Ross, Mark A. Preston, Justin R. Gregg, Simpa S. Salami, Fred Saad, Christopher M. Pieczonka, Ronald F. Tutrone, Joelle Hamilton, David S. Morris, …
The Journal of urology, v 215(5S2), e4
May 2026
Featured in Collection :   Drexel's Newest Publications

Metrics

1 Record Views

Details

Logo image